Investigating the potential anticancer activities of antibiotics as topoisomerase II inhibitors and DNA intercalators: in vitro, molecular docking, molecular dynamics, and SAR studies. (31st December 2023)

• Record Type: Journal Article
• Authors: Farouk, Faten; Elmaaty, Ayman Abo; Elkamhawy, Ahmed; Tawfik, Haytham O.; Alnajjar, Radwan; Abourehab, Mohammed A. S.; Saleh, Mohamed A.; Eldehna, Wagdy M.; Al‐Karmalawy, Ahmed A.
• Is Part Of: Journal of enzyme inhibition and medicinal chemistry. Volume 38:Number 1(2023)
• Publication Date: 2023-12-31
• Subjects: Antibiotics -- cytotoxicity -- topoisomerase II -- molecular docking and dynamics -- MM-GBSA; Enzyme inhibitors -- Periodicals; Enzyme Inhibitors -- periodicals; Biochemistry -- periodicals; 572.7
• DOI: 10.1080/14756366.2023.2171029
• Languages: English
• ISSNs: 1475-6366

Abstract

Abstract: Topoisomerase II (TOP-2) is a promising molecular target for cancer therapy. Numerous antibiotics could interact with biologically relevant macromolecules and provoke antitumor potential. Herein, molecular docking studies were used to investigate the binding interactions of 138 antibiotics against the human topoisomerase II-DNA complex. Followed by the MD simulations for 200 ns and MM-GBSA calculations. On the other hand, the antitumor activities of the most promising candidates were investigated against three cancer cell lines using doxorubicin (DOX) as a reference drug. Notably, spiramycin (SP ) and clarithromycin (CL ) showed promising anticancer potentials on the MCF-7 cell line. Moreover, azithromycin (AZ ) and CL exhibited good anticancer potentials against the HCT-116 cell line. Finally, the TOP-2 enzyme inhibition assay was carried out to confirm the proposed rationale. Briefly, potent TOP-2 inhibitory potentials were recorded for erythromycin (ER ) and roxithromycin (RO ). Additionally, a SAR study opened eyes to promising anticancer pharmacophores encountered by these antibiotics. Highlights: Molecular docking studies of 139 antibiotics against the topoisomerase II-DNA complex. SP, RO, AZ, CL, and ER were the most promising and commercially available candidates. Molecular dynamics simulations for 200 ns for the most promising five complexes. MM-GBSA calculations for the frontier five complexes. SP and CL showed promising anticancer potentials on the MCF-7 cell line, besides, AZ and CL exhibited good anticancer potentials against the HCT-116 cell line. Potent TOP-2 inhibitory potentials were recorded for ER and RO . Graphical Abstract: UF0001